| scholarly article | Q13442814 |
| P50 | author | Tomoaki Murakami | Q38322049 |
| Nagahisa Yoshimura | Q71014329 | ||
| Hirokazu Ohashi | Q114402174 | ||
| Tomonari Ojima | Q114407296 | ||
| Kiyoshi Suzuma | Q114407297 | ||
| Izumi Suzuma | Q114407298 | ||
| Masafumi Kurimoto | Q114407299 | ||
| Mihori Kita | Q114407304 | ||
| P2093 | author name string | Seiji Masuda | |
| Hitoshi Takagi | |||
| Daisuke Watanabe | |||
| Toshihiro Kobayashi | |||
| Shigeyuki Matsui | |||
| Masaya Nagao | |||
| Junichi Kiryu | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | erythropoietin | Q218706 |
| P304 | page(s) | 782-792 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy | |
| P478 | volume | 353 |
| Q48349526 | 3D endothelial cell spheroid/human vitreous humor assay for the characterization of anti-angiogenic inhibitors for the treatment of proliferative diabetic retinopathy. |
| Q36796695 | A chronic grey matter penumbra, lateral microvascular intussusception and venous peduncular avulsion underlie diabetic vitreous haemorrhage |
| Q50955798 | A high value of serum des-γ-carboxy prothrombin before hepatocellular carcinoma treatment can be associated with long-term liver dysfunction after treatment. |
| Q35679523 | A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy |
| Q50960506 | Absence of macrophage migration inhibitory factor reduces proliferative retinopathy in a mouse model. |
| Q38826645 | An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease |
| Q36659505 | Anemia and diabetic nephropathy |
| Q37375095 | Anemia in the preterm infant: erythropoietin versus erythrocyte transfusion--it's not that simple |
| Q41883466 | Angiogenic Factors and Cytokines in Diabetic Retinopathy |
| Q28262797 | Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy |
| Q34295974 | Antiangiogenic therapy for ischemic retinopathies |
| Q40009474 | Antiapoptotic properties of erythropoietin: novel strategies for protection of retinal pigment epithelial cells |
| Q37404573 | Antisense oligonucleotide therapy in diabetic retinopathy |
| Q37288064 | Apelin-13 induces proliferation, migration, and collagen I mRNA expression in human RPE cells via PI3K/Akt and MEK/Erk signaling pathways |
| Q33864879 | Aqueous humor erythropoietin levels in open-angle glaucoma patients with and without TTR V30M familial amyloid polyneuropathy |
| Q33795017 | Aqueous levels of erythropoietin in acute retinal vein occlusion with macular edema |
| Q34292293 | Asialoerythropoietin ameliorates bleomycin-induced acute lung injury in rabbits by reducing inflammation |
| Q36123609 | Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States |
| Q41444553 | Association of erythropoietin gene polymorphisms with retinopathy in a Chinese cohort with type 2 diabetes mellitus |
| Q41457604 | Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina |
| Q33728352 | Betacellulin Induces Increased Retinal Vascular Permeability in Mice |
| Q36467377 | Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review |
| Q36999068 | Control of erythropoietin gene expression and its use in medicine |
| Q37221516 | Current and future approaches in the prevention and treatment of diabetic retinopathy. |
| Q38690858 | Current and future chemical therapies for treating anaemia in chronic kidney disease |
| Q43085062 | Diabetes changes expression of genes related to glutamate neurotransmission and transport in the Long-Evans rat retina |
| Q38542115 | Diabetic Retinopathy: Vascular and Inflammatory Disease. |
| Q37654732 | Diabetic nephropathy: a disorder of oxygen metabolism? |
| Q38088948 | Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology? |
| Q84482290 | Diabetic retinopathy |
| Q37230196 | Diabetic retinopathy is not associated with carbonic anhydrase gene polymorphisms |
| Q34263212 | Diabetic retinopathy risk factors: plasma erythropoietin as a risk factor for proliferative diabetic retinopathy |
| Q39445950 | Diabetic retinopathy: current understanding, mechanisms, and treatment strategies |
| Q38199730 | Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment |
| Q34448837 | Diabetic retinopathy: targeting vasoregression |
| Q37733102 | Dietary hyperglycemia, glycemic index and metabolic retinal diseases |
| Q28750073 | Differential modulation of angiogenesis by erythropoiesis-stimulating agents in a mouse model of ischaemic retinopathy |
| Q33868764 | Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization |
| Q37693793 | Disturbance of inorganic phosphate metabolism in diabetes mellitus: its relevance to the pathogenesis of diabetic retinopathy |
| Q24195000 | Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants |
| Q24200642 | Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants |
| Q24245418 | Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants |
| Q37776148 | Effect of systemic medications on onset and progression of diabetic retinopathy |
| Q46689938 | Elevated erythropoietin mRNA and protein concentrations in the developing human eye. |
| Q43230857 | Enalapril alters expression of key growth factors in experimental diabetic retinopathy |
| Q36494891 | Endogenous erythropoietin protects neuroretinal function in ischemic retinopathy |
| Q51392817 | Endogenous plasma erythropoietin, cardiovascular mortality and all-cause mortality in renal transplant recipients. |
| Q30433579 | Endothelial progenitor cells (EPCs) mobilized and activated by neurotrophic factors may contribute to pathologic neovascularization in diabetic retinopathy |
| Q30908819 | Erythropoetin receptor expression in the human diabetic retina |
| Q37098040 | Erythropoietic agents and the elderly |
| Q86893314 | Erythropoietin |
| Q42739497 | Erythropoietin activates mitochondrial biogenesis and couples red cell mass to mitochondrial mass in the heart |
| Q64093623 | Erythropoietin and Friedreich Ataxia: Time for a Reappraisal? |
| Q39432541 | Erythropoietin and Its Angiogenic Activity |
| Q87923641 | Erythropoietin and retinopathy of prematurity: a meta-analysis |
| Q33288270 | Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression |
| Q36404124 | Erythropoietin deficiency decreases vascular stability in mice. |
| Q35909929 | Erythropoietin in brain development and beyond |
| Q47806649 | Erythropoietin in diabetic retinopathy. |
| Q26744850 | Erythropoietin in ophthalmology: A literature review |
| Q36146016 | Erythropoietin levels in aqueous humor of patients with glaucoma |
| Q37968179 | Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy |
| Q34576332 | Erythropoietin protects adult retinal ganglion cells against NMDA-, trophic factor withdrawal-, and TNF-α-induced damage |
| Q39820483 | Erythropoietin therapy for early diabetic retinopathy through its protective effects on retinal pericytes |
| Q37862940 | Erythropoietin: a hormone with multiple functions |
| Q42972651 | Erythropoietin: when liability becomes asset in neurovascular repair |
| Q35923796 | Expression of FLT4 in hypoxia-induced neovascular models in vitro and in vivo |
| Q36025893 | Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathy |
| Q41943468 | Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes |
| Q37197614 | Gene-gene interaction of erythropoietin gene polymorphisms and diabetic retinopathy in Chinese Han. |
| Q37164288 | Genetic contributions to the development of retinopathy of prematurity |
| Q37217851 | Genetic susceptibility of diabetic retinopathy. |
| Q37148800 | Genetics in diabetic retinopathy: current concepts and new insights |
| Q43170787 | Geographic altitude, ocular diseases and injuries |
| Q43289952 | High-dose erythropoietin does not exacerbate retinopathy of prematurity in rats |
| Q37667292 | Hypoxia-Inducible Factor-1α Target Genes Contribute to Retinal Neuroprotection |
| Q41131632 | Hypoxia-inducible factor expression in human RPE cells |
| Q37803482 | Hypoxia. 1. Intracellular sensors for oxygen and oxidative stress: novel therapeutic targets |
| Q38960055 | IGF-1 in retinopathy of prematurity, a CNS neurovascular disease |
| Q37109989 | Immunological mechanisms in the pathogenesis of diabetic retinopathy |
| Q37494247 | Impaired function of circulating CD34(+) CD45(-) cells in patients with proliferative diabetic retinopathy |
| Q45905920 | Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment. |
| Q38923061 | Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac). |
| Q35405149 | Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy |
| Q46362748 | Intravitreal recombinant human erythropoietin: a safety study in rabbits |
| Q64930168 | Intravitreous high expression level of netrin-1 in patients with proliferative diabetic retinopathy. |
| Q93044894 | Intussusceptive Vascular Remodeling Precedes Pathological Neovascularization |
| Q33937354 | Involvement of erythropoietin in retinal ischemic preconditioning. |
| Q43137838 | Isolation and characterization of goat retinal microvascular endothelial cells |
| Q42787068 | Landmark advances in the development of erythropoietin |
| Q43117950 | Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina |
| Q37678807 | Mediators of ocular angiogenesis |
| Q35801354 | Micro- and Nanoparticles for Treating Cardiovascular Disease |
| Q37617260 | MicroRNA signature and function in retinal neovascularization |
| Q26822476 | Microvascular complications and diabetic retinopathy: recent advances and future implications |
| Q54376807 | Netrin-1 overexpression in oxygen-induced retinopathy correlates with breakdown of the blood-retina barrier and retinal neovascularization. |
| Q90060268 | Network Pharmacology-based Investigation of the Underlying Mechanism of Panax Notoginseng Treatment of Diabetic Retinopathy |
| Q33887925 | Neurodegeneration: An early event of diabetic retinopathy |
| Q38050159 | Neuropeptides and diabetic retinopathy |
| Q38009713 | Neuroprotection in diabetic retinopathy |
| Q37897477 | New era for drug discovery and development in renal disease |
| Q38013679 | Novel targets against retinal angiogenesis in diabetic retinopathy |
| Q39329553 | Phosphodiesterase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidney |
| Q43125084 | Pigment epithelium-derived factor inhibits erythropoietin-induced retinal endothelial cell angiogenesis by suppression of PI3K/Akt pathway |
| Q47361893 | Plasma levels of hypoxia-regulated factors in patients with age-related macular degeneration. |
| Q35225120 | Possibility of enhanced risk of retinal neovascularization in repeated blood donors: blood donation and retinal alteration |
| Q37423520 | Prediction of proliferative diabetic retinopathy with hemoglobin level |
| Q90476018 | Prethreshold retinopathy of prematurity: VEGF inhibition without VEGF inhibitors |
| Q36657594 | Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications |
| Q60939604 | Radioprotective Activity and Preliminary Mechanisms of -oxalyl-d-phenylalanine (NOFD) In Vitro |
| Q50054673 | Rapidly progressive neovascular glaucoma following coronary artery bypass graft surgery in a patient with type 1 diabetes mellitus: a case report |
| Q24649547 | Recent trends in erythropoietin-mediated neuroprotection |
| Q37375616 | Recombinant human erythropoietin improves neurological outcomes in very preterm infants |
| Q37098594 | Regression activity that is naturally present in vitreous becomes ineffective as patients develop proliferative diabetic retinopathy |
| Q37274155 | Retinal expression of small non-coding RNAs in a murine model of proliferative retinopathy. |
| Q60439193 | Retinopathy of prematurity |
| Q68289981 | Retinopathy of prematurity |
| Q88428684 | Retinopathy of prematurity: a review of risk factors and their clinical significance |
| Q33585466 | Retinopathy of prematurity: the need for prevention |
| Q38855251 | Revisiting the role of erythropoietin for treatment of ocular disorders. |
| Q35587285 | Safety and angiogenic effects of systemic gene delivery of a modified erythropoietin |
| Q37106306 | Safety of intravitreally administered recombinant erythropoietin (an AOS thesis) |
| Q42915712 | Simvastatin suppresses expression of angiogenic factors in the retinas of rats with streptozotocin-induced diabetes |
| Q35085010 | Sirtuin1 over-expression does not impact retinal vascular and neuronal degeneration in a mouse model of oxygen-induced retinopathy. |
| Q38145185 | Structural changes in individual retinal layers in diabetic macular edema |
| Q33379554 | Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy |
| Q35651774 | Suppression of retinal neovascularization by lentivirus-mediated netrin-1 small hairpin RNA. |
| Q34725972 | Survival and proliferative roles of erythropoietin beyond the erythroid lineage |
| Q34972210 | Targeting Neovascularization in Ischemic Retinopathy: Recent Advances |
| Q36040633 | The Efficacy of Propranolol in Retinopathy of Prematurity and its Correlation with the Platelet Mass Index |
| Q34924454 | The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy. |
| Q33891194 | The effect of erythropoietin on the severity of retinopathy of prematurity |
| Q38150855 | The evolving treatment options for diabetic macular edema |
| Q35768528 | The genetic control of avascular area in mouse oxygen-induced retinopathy |
| Q57165717 | The genetics of retinopathy of prematurity: a model for neovascular retinal disease |
| Q30495106 | The mouse retina as an angiogenesis model |
| Q38101684 | The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge |
| Q34100527 | The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier--implications for the pathogenesis of diabetic retinopathy. |
| Q36674594 | The role of Rds in outer segment morphogenesis and human retinal disease |
| Q36352011 | The role of erythropoietin in myocardial protection: potential mechanisms and applications |
| Q46330877 | The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis |
| Q37358669 | Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system |
| Q58606867 | Time-dependent changes in hypoxia- and gliosis-related factors in experimental diabetic retinopathy |
| Q38176752 | Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer |
| Q51827148 | Two-photon microscopy of a Flt1 peptide-hyaluronate conjugate. |
| Q37625883 | Understanding ischemic retinopathies: emerging concepts from oxygen-induced retinopathy. |
| Q38249050 | Use of erythropoietin is associated with threshold retinopathy of prematurity (ROP) in preterm ELBW neonates: a retrospective, cohort study from two large tertiary NICUs in Italy |
| Q47209788 | Use of recombinant human erythropoietin and risk of severe retinopathy in extremely low-birth-weight infants |
| Q35186649 | VEGF mRNA and protein concentrations in the developing human eye. |
| Q38560836 | VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis |
| Q35197956 | Vascular cell-adhesion molecule-1 plays a central role in the proangiogenic effects of oxidative stress |
| Q36929380 | Vascular endothelial growth factor in eye disease |
| Q33593437 | Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema |
| Q38293676 | Vitreous humor in the pathologic scope: insights from proteomic approaches. |
| Q46452525 | Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema |
| Q27028225 | Vitreous mediators in retinal hypoxic diseases |
| Q93659644 | What's new in the other general journals |
| Q90249957 | Wnt Signaling in vascular eye diseases |
Search more.